Patent · US Active

11β-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones

US7473709B2 · kind B2 · utility

0Cited by

5References

7Claims

0Family size

Assignee

Bayer Schering Pharma AG · DE

Inventors

Sven Ring · Jena, DE
Gerd Schubert · Jena, DE
Lothar Sobek · Jena, DE

Key dates

Filing date	Dec 7, 2006
Grant date	Jan 6, 2009
Priority date	—
Expiry date	Feb 12, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present patent application relates to 11β-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I:wherein Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.